

Jamie P Dwyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6416459/publications.pdf>

Version: 2024-02-01

29
papers

1,432
citations

516710

16
h-index

526287

27
g-index

29
all docs

29
docs citations

29
times ranked

2122
citing authors

#	ARTICLE	IF	CITATIONS
1	Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience. <i>Journal of Cardiac Failure</i> , 2022, 28, 21-31.	1.7	8
2	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. <i>Kidney International</i> , 2022, 101, 174-184.	5.2	53
3	Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials. <i>Heart</i> , 2022, 108, 1281-1289.	2.9	18
4	Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study. <i>Kidney360</i> , 2022, 3, 1253-1262.	2.1	5
5	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021, 44, 1805-1815.	8.6	49
6	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 801.	6.1	26
7	Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice. <i>JAMA Internal Medicine</i> , 2020, 180, 1655.	5.1	52
8	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1700-1711.	0.7	107
9	COVID-19 and the Inpatient Dialysis Unit. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 720-722.	4.5	77
10	Assessment of Blood Pressure: Techniques and Implications From Clinical Trials. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 87-91.	1.4	2
11	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 606-617.	11.4	482
12	Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. <i>New England Journal of Medicine</i> , 2019, 380, 791-793.	27.0	140
13	439. Iclaprim Use for Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is Not Associated with Hyperkalemia: Phase 3 REVIVE Studies. <i>Open Forum Infectious Diseases</i> , 2019, 6, S218-S218.	0.9	0
14	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. <i>Circulation</i> , 2019, 139, 366-375.	1.6	32
15	Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). <i>American Journal of Kidney Diseases</i> , 2018, 71, 352-361.	1.9	104
16	Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. <i>PLoS ONE</i> , 2018, 13, e0203305.	2.5	14
17	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. <i>Lancet</i> , 2018, 392, 2269-2279.	13.7	70
18	We Give Too Much Intravenous Iron. <i>Seminars in Dialysis</i> , 2016, 29, 309-311.	1.3	2

#	ARTICLE	IF	CITATIONS
19	FP590FERRIC CITRATE (FC) AS A PHOSPHATE BINDER IN PERITONEAL DIALYSIS (PD). Nephrology Dialysis Transplantation, 2015, 30, iii270-iii270.	0.7	0
20	The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. American Journal of Kidney Diseases, 2015, 66, 479-488.	1.9	41
21	Kidney Dysfunction and Left Ventricular Assist Device Support: A Comprehensive Perioperative Review. CardioRenal Medicine, 2015, 5, 48-60.	1.9	29
22	Does Renal Dysfunction and Method of Bridging Support Influence Heart Transplant Graft Survival?. Annals of Thoracic Surgery, 2014, 98, 835-841.	1.3	17
23	Guidelines and Straitjackets: Blood Pressure Targets in the Era of the Eighth Joint National Committee. American Journal of Kidney Diseases, 2014, 63, 895-899.	1.9	2
24	Optimizing Blood Pressure Control in Patients With Nondiabetic Glomerular Disease. Advances in Chronic Kidney Disease, 2014, 21, 200-204.	1.4	4
25	Ferric citrate: a novel phosphate-binding agent. Expert Review of Endocrinology and Metabolism, 2013, 8, 13-19.	2.4	5
26	Nonproteinuric Diabetic Nephropathy. Medical Clinics of North America, 2013, 97, 53-58.	2.5	27
27	Dose-Response and Efficacy of Ferric Citrate to Treat Hyperphosphatemia in Hemodialysis Patients: A Short-term Randomized Trial. American Journal of Kidney Diseases, 2013, 61, 759-766.	1.9	55
28	Membranous glomerulopathy with superimposed pauci-immune necrotizing crescentic glomerulonephritis. CKJ: Clinical Kidney Journal, 2012, 5, 587-590.	2.9	4
29	Evaluation of Renal Artery Stenosis in Dialysis Patients. Seminars in Dialysis, 2009, 22, 519-523.	1.3	7